PODCAST: PSA testing in general practice - screening, assessment and monitoring
About the Podcast
Prostate cancer is the most diagnosed cancer and the second most common cause of cancer-related deaths in Australian males. Therefore, the screening, assessment, diagnosis and treatment of this disease is vital for general practitioners.
However, there has always been conflicting advice on whether a GP should order PSA (prostate specific antigen) testing for their patients, due to the ambiguity around the potential benefits and risks of the test. Since the existing guidelines were released in 2015, there have been significant advancements in technologies available to diagnose and monitor prostate cancer with better outcomes for patients.
Key Points Addressed in this Podcast
-
PSA testing best-practice
-
Harm minimisation to reduce over-diagnosis and treatment
-
Why active surveillance is safe and appropriate for low grade cancers
-
How to support patients who are anxious on active surveillance
Free On-Demand Webinar
Join us in this webinar as we discuss the advancements in screening and assessment that can inform contemporary care in primary health settings. View the webinar here: Prostate health: advances in screening and assessment
Additional Practitioner Resources
For health professionals: The evolution of PSA testing | Healthy Male
Blog News — A/Prof Jeremy Grummet – Melbourne Urological Surgeon
Modern paradigms for prostate cancer detection and management | The Medical Journal of Australia
Additional Patient Resources
Prostate Cancer Specialist Telenursing Service | PCFA Ph: 1800 22 00 99
Prostate Cancer Specialist Nursing Service | PCFA
Podcast Partner
This podcast is bought to you by Healthy Male. Additional learning resources including webinars, online learning modules and blogs can be viewed here.
Assoc Prof Jeremy Grummet is a urological surgeon with specific training and expertise in urological cancers. He is a pioneer of focal therapy for intermediate-risk localised prostate cancer, having started practising focal therapy in 2015 and is co-principal investigator on the LIBERATE focal brachytherapy clinical registry.
He also performs MRI-targeted transperineal biopsy for maximal accuracy and minimal risk in prostate cancer diagnosis. As a strong advocate of active surveillance for low-risk prostate cancer to minimise unnecessary treatment, Jeremy was a site investigator at Alfred Health on the PRIAS study, the largest worldwide study assessing outcomes for patients on active surveillance. Jeremy is an expert advisor for Healthy Male.
Become a member and get unlimited access to 100s of hours of premium education.
Learn moreMedcast is thrilled to announce a new collaboration with the University of Wollongong’s Graduate School of Medicine. The $2.7M MRFF grant focuses on reducing the inappropriate prescription of antibiotics, a key factor in the development of antimicrobial resistance (AMR).
Duc, a 57 year old accountant, presents to you one afternoon with a recent episode of slurred speech...
Successful resuscitation attempts rely on the optimisation of cerebral and coronary perfusion. For this to occur it is important to work like a NASCAR pit crew and deliver high performance CPR.